Diagnostic marker for lung cancer through microarray analysis

Dr. Kate Olson's Lab is interested to expand these analysis to comparisons between human normal lung tissue and human lung tumor tissue. In hopes that this will help in finding a diagnostic marker for lung cancer. Since there will be more variability between these samples, we would like to get preliminary data on ten normal lung tissue and ten lung tumor tissues from the same patient. We have already analyzed 4 cell lines and we saw gene expression variability related to how metastatic the cell lines were. This has been written and submitted for publication. We would like to expand these analysis to comparisons between human normal lung tissue and human lung tumor tissue. We hope that this will help in finding a diagnostic marker for lung cancer. Since there will be more variability between these samples, we would like to get preliminary data on ten normal lung tissue and ten lung tumor tissues from the same patient. The samples were dissected by a pathologist prior to extraction to maximize the amount of normal tissue included in the tumor samples. RNA samples from non tumor and tumor lung cancer patients were received by Core E. The RNA was amplified, labeled, and hybridized to the GLYCOv3 microarrays.

凯特·奥尔森（Kate Olson）博士的实验室拟将现有分析拓展至人类正常肺组织与肺肿瘤组织的对比研究，以期发掘肺癌的诊断标志物。鉴于此类样本间的异质性更高，本研究团队希望获取同一患者来源的10份正常肺组织与10份肺肿瘤组织的初步实验数据。
此前我们已完成4种细胞系的分析，观察到与细胞系转移潜能相关的基因表达差异，相关研究论文已撰写完成并提交待刊。
我们计划将现有分析再次拓展至人类正常肺组织与肺肿瘤组织的对比研究，以期发掘肺癌的诊断标志物。鉴于此类样本间的异质性更高，本研究团队希望获取同一患者来源的10份正常肺组织与10份肺肿瘤组织的初步实验数据。
样本在提取前已由病理学家进行解剖处理，以最大化肿瘤样本中正常组织的占比。
Core E已接收来自非肿瘤个体及肺癌患者的RNA样本。
上述RNA样本经扩增、标记后，与GLYCOv3微阵列完成杂交。